Equity Overview
Price & Market Data
Price: $1.33
Daily Change: +$0.015 / 1.13%
Daily Range: $1.32 - $1.35
Market Cap: $82,036,936
Daily Volume: 83,096
Performance Metrics
1 Week: 4.76%
1 Month: %
3 Months: 3.13%
6 Months: -11.41%
1 Year: 7.76%
YTD: 8.20%
Company Details
Employees: 49
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.